Primary ciliary dyskinesia - Pipeline Insight, 2021

Publisher Name :
Date: 12-Oct-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Primary Ciliary Dyskinesia - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Primary Ciliary Dyskinesia Understanding

Primary Ciliary Dyskinesia: Overview

Primary ciliary dyskinesia (PCD) is usually an autosomal recessive genetic condition in which the microscopic organelles (cilia) in the respiratory system have defective function. Ciliary dysfunction prevents the clearance of mucous from the lungs, paranasal sinuses and middle ears. Bacteria and other irritants in the mucous lead to frequent respiratory infections. Symptoms often begin shortly after birth and can include coughing, gagging, choking and lung atelectasis (neonatal respiratory distress). Affected individuals often experience chronic sinus, middle ear and lung infections as well as chronic coughing, excess mucus and hearing loss. Primary ciliary dyskinesia is diagnosed definitively through examination of lung or sinus tissue obtained from a biopsy or through genetic testing. Specific structural defects that are present in these tissues can be detected under an electron microscope. Airway clearance therapy is used to keep the lung tissue healthy for as long as possible. This therapy may include routine washing and suctioning of the sinus cavities and ear canals. Antibiotics, bronchodilators, steroids and mucus thinners (mucolytics) are also used to treat PCD.

"Primary Ciliary Dyskinesia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Ciliary Dyskinesia pipeline landscape is provided which includes the disease overview and Primary Ciliary Dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Primary Ciliary Dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Ciliary Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Primary Ciliary Dyskinesia R&D. The therapies under development are focused on novel approaches to treat/improve Primary Ciliary Dyskinesia.

Primary Ciliary Dyskinesia Emerging Drugs Chapters

This segment of the Primary Ciliary Dyskinesia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Ciliary Dyskinesia Emerging Drugs

- P 1037: Parion Sciences

Epithelial sodium channel (ENaC) inhibitors are designed to block the sodium channels on the airway surfaces. In pulmonary diseases, such as chronic obstructive pulmonary disease, cystic fibrosis and primary ciliary dyskinesia, where there is a build-up of excessively concentrated mucus, preclinical models have demonstrated that blocking ENaC hydrates the mucus on the lung surface. Hydration of airway mucus restores airway clearance and improves lung function. P-1037 is a novel, long acting ENaC Inhibitor that was well tolerated at the doses tested in multiple clinical trials in healthy volunteers and patients with either cystic fibrosis or primary ciliary dyskinesia. The company has reached an agreement with Vertex Pharmaceuticals, Inc. to reacquire the pulmonary rights to epithelial sodium channel (ENaC) inhibitors developed under a collaboration announced between the parties in 2015. Under this agreement, Vertex is eligible to receive future undisclosed royalties based upon commercial success. FDA has also Granted Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation to Parion Sciences P-1037 Inhalation Solution for the Treatment of Primary Ciliary Dyskinesia.

Further product details are provided in the report……..

Primary Ciliary Dyskinesia: Therapeutic Assessment

This segment of the report provides insights about the different Primary Ciliary Dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Primary Ciliary Dyskinesia

There are approx. 4+ key companies which are developing the therapies for Primary Ciliary Dyskinesia. The companies which have their Primary Ciliary Dyskinesia drug candidates in the most advanced stage, i.e. Phase II include, Parion Sciences

- Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Primary Ciliary Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Ciliary Dyskinesia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Ciliary Dyskinesia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Ciliary Dyskinesia drugs.

Primary Ciliary Dyskinesia Report Insights

- Primary Ciliary Dyskinesia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Primary Ciliary Dyskinesia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Primary Ciliary Dyskinesia drugs?

- How many Primary Ciliary Dyskinesia drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Ciliary Dyskinesia?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Primary Ciliary Dyskinesia therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Primary Ciliary Dyskinesia and their status?

- What are the key designations that have been granted to the emerging drugs?

Primary ciliary dyskinesia - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Primary Ciliary Dyskinesia: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
* Comparative Analysis
Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
P 1037: Parion Sciences
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
* Comparative Analysis
Research programme: RNA and gene therapeutics - ReCode Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
Primary Ciliary Dyskinesia Key Companies
Primary Ciliary Dyskinesia Key Products
Primary Ciliary Dyskinesia- Unmet Needs
Primary Ciliary Dyskinesia- Market Drivers and Barriers
Primary Ciliary Dyskinesia- Future Perspectives and Conclusion
Primary Ciliary Dyskinesia Analyst Views
Primary Ciliary Dyskinesia Key Companies
Appendix

List of Tables

Table 1 Total Products for Primary Ciliary Dyskinesia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Primary Ciliary Dyskinesia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global and China Staphylococcal Infection Drugs Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 132
    Staphylococcal Infection Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Staphylococcal Infection Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuses on......
  • Global and China Equine Supplement Products Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 141
    Equine Supplement Products market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Equine Supplement Products market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuses on the Equ......
  • Global and China Postoperative Pain Therapeutics Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 147
    Postoperative Pain Therapeutics market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Postoperative Pain Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuses ......
  • Global and China Translational Regenerative Medicine Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 141
    Translational Regenerative Medicine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Translational Regenerative Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report ......
  • Global and Japan Haemophilia Treatment Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 141
    Haemophilia Treatment market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Haemophilia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For Japan market, this report focuses on the Haemophilia T......
  • Global and China Bispecific Antibodies for Cancer Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 135
    Bispecific Antibodies for Cancer market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Bispecific Antibodies for Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuse......
  • Global and United States Embolization Microsphere Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 132
    Embolization Microsphere market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Embolization Microsphere market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For United States market, this report focuses on the......
  • Global and Japan Antiretroviral Drug Market Size, Status and Forecast 2021-2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 97
    Global Antiretroviral Drug Scope and Market Size Antiretroviral Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antiretroviral Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type......
  • Global and Japan Chemotherapy Drug Market Size, Status and Forecast 2021-2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 95
    Global Chemotherapy Drug Scope and Market Size Chemotherapy Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs